Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody-Reference-Cited by-同舟云学术

Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody

Published:2020-03 Issue:3 Volume:28 Page:794-804
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Kanaya Nobuhiko,Kuroda Shinji,Kakiuchi Yoshihiko,Kumon Kento,Tsumura Tomoko,Hashimoto Masashi,Morihiro Toshiaki,Kubota Tetsushi,Aoyama Katsuyuki,Kikuchi Satoru,Nishizaki Masahiko,Kagawa Shunsuke,Tazawa Hiroshi,Mizuguchi Hiroyuki,Urata Yasuo,Fujiwara Toshiyoshi

Funder

Japan Society for the Promotion of Science

Japan Agency for Medical Research and Development

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference49 articles.

1. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential;Sharma;Cell,2015

2. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013

3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol.,2015

4. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057);Horn;J. Clin. Oncol.,2017

5. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer;Brahmer;N. Engl. J. Med.,2015

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. p53-armed oncolytic virotherapy induces abscopal effect in osteosarcoma by promoting immunogenic cell death;Molecular Therapy: Oncology;2024-09

2. Oncolytic viruses facilitate tumor immunotherapy;SCIENTIA SINICA Vitae;2024-09-01

3. Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B‐NIT);Cancer Science;2024-08-09

4. The investigation of oncolytic viruses in the field of cancer therapy;Frontiers in Oncology;2024-07-10

5. Is oncolytic adenoviral-mediated immunotherapy through p53-overexpression the solution to refractory pancreatic ductal adenocarcinoma?;Expert Review of Gastroenterology & Hepatology;2024-06-02